Citations

Showing 10 of 108083 citations.

The decline in stroke hospitalization due to COVID‐19 is unrelated to COVID‐19 intensity
Šedová, Petra , Kent, Julia Anna, Bryndziar, Tomáš , Šrámek, Martin , Škoda, Ondřej, Sramkova, Tereza, Pokorová, Kateřina, Littnerová, Simona , Brown, Robert D. , Mikulík, Robert , Mikulik, Robert , Jarkovský, Jiří , Tomek, Aleš , Šrámková, Tereza

Mayo Clinic

European Journal of Neurology | December 13, 2022 | Volume: 30 | Issue: 4 | Pages: 943-950

10.1111/ene.15664 | PMID 36511840 Get It

AbstractBackground and PurposeDuring the coronavirus disease 2019 (COVID‐19) pandemic many countries reported a decline in stroke volumes. The aim of this study was to analyze if the decline was related to the intensity of the COVID‐19 pandemic.MethodsThe first pandemic year (1 March 2020 to 28 February 2021) overall and during the three COVID‐19 waves were compared with the preceding year. Volumes of acute ischaemic stroke (AIS), subarachnoid hemorrhage, intracerebral hemorrhage and recanalization treatments (intravenous thrombolysis [IVT] and mechanical thrombectomy [MT]) were obtained from the National Register of Reimbursed Health Services. Door‐to‐needle time, onset‐to‐door time and National Institutes of Health Stroke Scale at admission were obtained from the Registry of Stroke Care Quality.ResultsDuring the pandemic year compared to the preceding year there were 26,453 versus 28,771 stroke admissions, representing an 8.8% decline (p < 0.001). The declines (−10%, −11%, −19%) appeared in COVID‐19 waves (spring 2020, autumn 2020, winter 2021) except for an increase (2%) during summer 2020. Admissions for AIS declined by 10.2% (p < 0.001), whilst hemorrhagic stroke volumes were minimally decreased. The absolute volumes of IVT and MT decreased by 9.4% (p < 0.001) and 5.7% (p = 0.16), respectively. However, the proportions of ischaemic stroke patients receiving IVT (18% vs. 18%; p = 0.72) and MT (6% vs. 6%; p = 0.28) remained unchanged.ConclusionsThere was a decline in stroke admissions, but such decline was not related to COVID‐19 incidence. The frequency of use of recanalization procedures (IVT, MT) and times (onset‐to‐door time, door‐to‐needle time) in AIS were preserved in the Czech Republic during the first year of the pandemic.
Risk Factors and Outcomes of Invasive Aspergillosis in Kidney Transplant Recipients: A Case-Control Study of United States Renal Data System Data
Friedman, Daniel , Johnson, Bradley K. , Kremers, Walter K. , Vergidis, Paschalis , Friedman, Daniel Z P , Vergidis, Paschalis , Kremers, Walter K , Beam, Elena

Mayo Clinic

Clinical Infectious Diseases | December 13, 2022 | Volume: 76 | Issue: 8 | Pages: 1431-1439

10.1093/cid/ciac927 | PMID 36516420 Get It

AbstractBackgroundKidney transplant recipients are at increased risk for invasive aspergillosis (IA), a disease with poor outcomes and substantial economic burden. We aimed to determine risk factors for posttransplant IA by using a national database and to assess the association of IA with mortality and allograft failure.MethodsUsing the United States Renal Data System database, we performed a retrospective case-control study of patients who underwent kidney transplant from 1998 through 2017. To evaluate risk factors for IA, we performed conditional logistic regression analysis by comparing characteristics between IA-infected patients and their matched uninfected controls. We performed Cox regression analysis to evaluate the effects of IA on mortality and death-censored allograft failure.ResultsWe matched 359 patients with IA to 1436 uninfected controls (1:4). IA was diagnosed at a median of 22.5 months (interquartile range, 5.4–85.2 months) after kidney transplant. Risk factors for IA were Black/African American race, duration of pretransplant hemodialysis, higher Elixhauser Comorbidity Index score, weight loss, chronic pulmonary disease, need for early posttransplant hemodialysis, and a history of cytomegalovirus infection. Receiving an allograft from a living donor was protective against IA. IA was a strong independent predictor of 1-year mortality (adjusted hazard ratio [aHR], 5.02 [95% confidence interval {CI}, 3.58–7.04], P &lt; .001). Additionally, IA was associated with 1-year allograft failure (aHR, 3.37 [95% CI, 1.96–5.77], P &lt; .001).ConclusionsOur findings emphasize the importance of timely transplant to mitigate the risk of posttransplant IA. An individualized approach to disease prevention is essential to decrease mortality and allograft failure.
Management of REM sleep behavior disorder: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment
Howell, Michael J. , Malkani, Roneil G. , Roland, Joshua P. , McCarter, Stuart J. , Carandang, Gerard, Kazmi, Uzma, Ramar, Kannan , Howell, Michael J , McCarter, Stuart J , Avidan, Alon Y. , Foldvary‐Schaefer, Nancy , During, Emmanuel , Zak, Rochelle , Kazmi, Uzma

Mayo Clinic

Journal of Clinical Sleep Medicine | December 13, 2022 | Volume: 19 | Issue: 4 | Pages: 769-810

10.5664/jcsm.10426 | PMID 36515150 Get It

Management of REM sleep behavior disorder: an American Academy of Sleep Medicine clinical practice guideline
Howell, Michael J. , Malkani, Roneil G. , Roland, Joshua P. , McCarter, Stuart J. , Carandang, Gerard, Kazmi, Uzma, Ramar, Kannan , Howell, Michael J , McCarter, Stuart J , Avidan, Alon Y. , Foldvary‐Schaefer, Nancy , During, Emmanuel , Zak, Rochelle , Kazmi, Uzma

Mayo Clinic

Journal of Clinical Sleep Medicine | December 13, 2022 | Volume: 19 | Issue: 4 | Pages: 759-768

10.5664/jcsm.10424 | PMID 36515157 Get It

Deregulation of SPOP in Cancer
Zhang, Hui , Jin, Xiaofeng , Huang, Haojie , Huang, Rui

Mayo Clinic

Cancer Research | December 13, 2022 | Volume: 83 | Issue: 4 | Pages: 489-499

10.1158/0008-5472.can-22-2801 | PMID 36512624 Get It

Abstract Speckle-type POZ protein (SPOP) is a substrate-binding adaptor of the CULLIN3/RING-box1 E3 ubiquitin ligase complex. SPOP is frequently mutated in prostate and endometrial cancers, whereas it is overexpressed in renal cell carcinoma (RCC). SPOP can mediate both degradable and nondegradable polyubiquitination of a number of substrates with diverse biological functions such as androgen receptor (AR), SRC-3, TRIM24, BRD4, PD-L1, 53BP1, GLP/G9a, c-Myc, SENP7, among others. Cancer-associated SPOP mutants often impair SPOP binding and polyubiquitination of its substrates to influence various cancer-relevant pathways, which include androgen/AR signaling, DNA repair and methylation, cellular stress surveillance, cancer metabolism, and immunity. Although SPOP is recognized as a tumor suppressor in prostate and endometrial cancers, it acts like an oncoprotein in RCC. This review provides an overview of the recent progress in understanding of the upstream regulators of SPOP and its downstream targets, highlights the significant impact of SPOP mutations and overexpression on cancer pathogenesis, and discusses the potential of targeting SPOP for cancer treatment.
Improving ultrasound‐based brachytherapy needle conspicuity by applying an echogenic coating
Brost, Eric E., Stish, Bradley J. , Lee, Christine U. , Deufel, Christopher L. , Brost, Eric, Urban, Matthew W.

Mayo Clinic

Medical Physics | December 13, 2022 | Volume: 50 | Issue: 3 | Pages: 1418-1427

10.1002/mp.16138 | PMID 36511174 Get It

AbstractBackgroundApplicator conspicuity in ultrasound‐guided brachytherapy procedures is commonly impaired by imaging artifacts or non‐ideal imaging geometry, which can slow down applicator position digitization and increase the geometric uncertainty of the delivered dose distribution.PurposeThe purpose of this study was to improve the conspicuity of high‐dose rate (HDR) brachytherapy needles under B‐mode ultrasound imaging by applying an echogenic surface coating. Our hypothesis was that an echogenic coating would reduce artifacts and improve needle visualization within regions of signal degradation.MethodsIn this study, 17‐gauge, 25‐cm long titanium HDR brachytherapy needles were coated with acoustically reflective microspheres over a 2.5 cm region starting from the needle tip. Three coating thicknesses (27 μm, 40 μm, 64 μm) were compared against an uncoated control needle. The coated and uncoated needles were imaged using B‐mode ultrasound in a tissue‐equivalent prostate phantom and in a cadaverous male pelvis using a transrectal probe. Needle conspicuity was assessed under multiple conditions: a single needle implant, an implant with multiple needles between the probe and the needle of interest, and an angled needle implant. All images were assessed qualitatively for needle conspicuity and the presence of artifacts and quantitatively using grey‐scale image intensity values.ResultsThe 64 μm echogenic coating reduced the magnitude of reverberation artifacts by 31 ± 14% and comet tail artifacts by 40%–70%. The echogenic coating also improved needle contrast, measured by the relative differences in signal intensity compared with the adjacent environment, when needles were angled up to 30° with respect to the transducer probe in the cadaver. The improvements in conspicuity and artifact reduction increased with increasing coating thickness. The performance of the needles coated with the 64 μm thickness was qualitatively superior and yielded high‐contrast, well‐circumscribed signals in the cadaverous male pelvis, even under situations where a needle was acoustically shadowed by multiple other needles.ConclusionsAn echogenic surface coating reduced imaging artifacts and improved needle conspicuity under realistic clinical conditions for ultrasound‐based prostate or gynecological brachytherapy. The improved conspicuity has the potential to improve the efficiency of needle placement and the accuracy of needle position digitization during brachytherapy procedures.
Benchmarking differential abundance analysis methods for correlated microbiome sequencing data
Yang, Lu , Chen, Jun

Mayo Clinic

Briefings in Bioinformatics | December 13, 2022 | Volume: 24 | Issue: 1 | Pages: No page available

10.1093/bib/bbac607 | PMID 36617187 Get It

Abstract Differential abundance analysis (DAA) is one central statistical task in microbiome data analysis. A robust and powerful DAA tool can help identify highly confident microbial candidates for further biological validation. Current microbiome studies frequently generate correlated samples from different microbiome sampling schemes such as spatial and temporal sampling. In the past decade, a number of DAA tools for correlated microbiome data (DAA-c) have been proposed. Disturbingly, different DAA-c tools could sometimes produce quite discordant results. To recommend the best practice to the field, we performed the first comprehensive evaluation of existing DAA-c tools using real data-based simulations. Overall, the linear model-based methods LinDA, MaAsLin2 and LDM are more robust than methods based on generalized linear models. The LinDA method is the only method that maintains reasonable performance in the presence of strong compositional effects.
A Compact Control System to Enable Automated Operation of Microfluidic Bioanalytical Assays
Gonzalez‐Suarez, Alan M. , Long, Alexander , Huang, XuHai, Revzin, Alexander , Gonzalez-Suarez, Alan M

Mayo Clinic

Biosensors | December 13, 2022 | Volume: 12 | Issue: 12 | Pages: 1160

10.3390/bios12121160 | PMID 36551127 Get It

We describe a control system for operating valve-enabled microfluidic devices and leverage this control system to carry out a complex workflow of plasma separation from 8 μL of whole blood followed by on-chip mixing of plasma with assay reagents for biomarker detection. The control system incorporates pumps, digital pressure sensors, a microcontroller, solenoid valves and off-the-shelf components to deliver high and low air pressure in the desired temporal sequence to meter fluid flow and actuate microvalves. Importantly, our control system is portable, which is suitable for operating the microvalve-enabled microfluidic devices in the point-of-care setting.
Oligomer Formation by Amyloid-β42 in a Membrane-Mimicking Environment in Alzheimer’s Disease
Rosenberry, Terrone L. , Zhou, Huan‐Xiang , Stagg, Scott M. , Paravastu, Anant K.

Mayo Clinic

Molecules | December 13, 2022 | Volume: 27 | Issue: 24 | Pages: 8804

10.3390/molecules27248804 | PMID 36557940 Get It

The brains of Alzheimer’s disease (AD) patients contain numerous amyloid plaques that are diagnostic of the disease. The plaques are primarily composed of the amyloidogenic peptides proteins Aβ40 and Aβ42, which are derived by the processing of the amyloid pre-cursor protein (APP) by two proteases called β-secretase and γ-secretase. Aβ42 differs from Aβ40 in having two additional hydrophobic amino acids, ILE and ALA, at the C-terminus. A small percentage of AD is autosomal dominant (ADAD) and linked either to the genes for the presenilins, which are part of γ-secretase, or APP. Because ADAD shares most pathogenic features with widespread late-onset AD, Aβ peptides have become the focus of AD research. Fibrils formed by the aggregation of these peptides are the major component of plaques and were initially targeted in AD therapy. However, the fact that the abundance of plaques does not correlate well with cognitive decline in AD patients has led investigators to examine smaller Aβ aggregates called oligomers. The low levels and heterogeneity of Aβ oligomers have made the determination of their structures difficult, but recent structure determinations of oligomers either formed or initiated in detergents have been achieved. We report here on the structures of these oligomers and suggest how they may be involved in AD.
Hematopoietic Stem Cell Transplantation in CSF1R-Related Leukoencephalopathy: Retrospective Study on Predictors of Outcomes
Dulski, Jarosław , White, Launia J. , Żur‐Wyrozumska, Kamila , Lund, Troy C. , Wszołek, Zbigniew K. , Wszolek, Z.K. , Lund, Troy C , Dulski, Jaroslaw , Heckman, Michael G.

Mayo Clinic

Pharmaceutics | December 13, 2022 | Volume: 14 | Issue: 12 | Pages: 2778

10.3390/pharmaceutics14122778 | PMID 36559271 Get It

Mutations in the CSF1R gene are the most common cause of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a neurodegenerative disease with rapid progression and ominous prognosis. Hematopoietic stem cell transplantation (HSCT) has been increasingly offered to patients with CSF1R-ALSP. However, different therapy results were observed, and it was not elucidated which patient should be referred for HSCT. This study aimed to determine predictors of good and bad HSCT outcomes in CSF1R-ALSP. We retrospectively analyzed 15 patients, 14 symptomatic and 1 asymptomatic, with CSF1R-ALSP that underwent HSCT. Median age of onset was 39 years, and the median age of HSCT was 43 years. Cognitive impairment was the most frequent initial manifestation (43%), followed by gait problems (21%) and neuropsychiatric symptoms (21%). Median post-HSCT follow-up was 26 months. Good outcomes were associated with gait problems as initial (p = 0.041) and predominant (p = 0.017) manifestation and younger age at HSCT (p = 0.044). Cognitive impairment as first manifestation was a predictor of a bad outcome (p = 0.016) and worsening of cognition post-HSCT (p = 0.025). In conclusion, gait problems indicated a milder phenotype with better response to HSCT and good therapy outcomes. In contrast, patients with a higher burden of cognitive symptoms were most likely not to benefit from HSCT.